Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04716712 · ClinicalTrials.gov registry record · Phase 4
Infant Mortality Reduction by the Mass Administration of Azithromycin
A Phase 4 study of Child Mortality, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 694,400
- Enrollment target
- 3
- Study locations
NCT04716712: Active Phase 4 study of Child Mortality, sponsored by University of California, San Francisco.
NCT04716712 is a Phase 4 study of Child Mortality that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 694,400 participants, above the 443-participant average among 9,235 other Phase 4 trials with a reported enrollment target (156649% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04716712, a Phase 4 study of Child Mortality, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 694,400 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.
Primary Outcome
a) Evaluate whether azithromycin integrated within the VAD+ platform reduces mortality in children aged 1-11 months old compared to placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (3)
Other
- Centre de Recherche en Sante de Nouna - Nouna
- Helen Keller International - Ouagadougou
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694,400 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 4 |
What the registry record for NCT04716712 still lists
NCT04716712 is an interventional study that assigns participants to a tested intervention. Its 694,400 participants enrollment target places it among the larger protocols in the corpus, above the 443-participant average among 9,235 other Phase 4 trials with a reported enrollment target (156649% higher).
The record links to 1 condition, with Child Mortality appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04716712 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT04716712 about?
NCT04716712 is a clinical study titled "Infant Mortality Reduction by the Mass Administration of Azithromycin". This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among chi...
What is the current status of trial NCT04716712?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 694,400 participants. The study started on 2021-10-04. Estimated completion is 2026-01-30.
What conditions does trial NCT04716712 study?
This clinical trial studies the following conditions: Child Mortality.
What interventions are being tested in trial NCT04716712?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04716712?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04716712 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04716712's enrollment target sits among peer trials
694,400 1st of 2000 higher than 2,000 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI